Optimization of troglitazone derivatives as potent anti-proliferative agents: Towards more active and less toxic compounds
- 1 August 2014
- journal article
- Published by Elsevier in European Journal of Medicinal Chemistry
- Vol. 83, 129-140
Abstract
No abstract availableKeywords
This publication has 31 references indexed in Scilit:
- Thiazolidine-2,4-diones: Progress towards multifarious applicationsBioorganic & Medicinal Chemistry, 2013
- Targeting Energy Metabolic and Oncogenic Signaling Pathways in Triple-negative Breast Cancer by a Novel Adenosine Monophosphate-activated Protein Kinase (AMPK) ActivatorJournal of Biological Chemistry, 2011
- Development of Novel Adenosine Monophosphate-Activated Protein Kinase ActivatorsJournal of Medicinal Chemistry, 2010
- Pharmacological Exploitation of the Peroxisome Proliferator-Activated Receptor γ Agonist Ciglitazone To Develop a Novel Class of Androgen Receptor-Ablative AgentsJournal of Medicinal Chemistry, 2008
- Disruption of ERα signalling pathway by PPARγ agonists: evidences of PPARγ-independent events in two hormone-dependent breast cancer cell linesBreast Cancer Research and Treatment, 2008
- PPAR Ligands as Potential Modifiers of Breast Carcinoma OutcomesPPAR Research, 2008
- Development of Small-Molecule Cyclin D1-Ablative AgentsJournal of Medicinal Chemistry, 2006
- Troglitazone and liver injuryHepatology, 2005
- Structure–activity requirements for the antiproliferative effect of troglitazone derivatives mediated by depletion of intracellular calciumBioorganic & Medicinal Chemistry Letters, 2004
- Use of the Peroxisome Proliferator-Activated Receptor (PPAR) γ Ligand Troglitazone as Treatment for Refractory Breast Cancer: A Phase II StudyBreast Cancer Research and Treatment, 2003